In a filing, Ocular Therapeutix Inc revealed its 10% Owner SUMMER ROAD LLC acquired Company’s shares for reported $7.0 million on Feb 26 ’24. In the deal valued at $7.52 per share,930,851 shares were bought. As a result of this transaction, SUMMER ROAD LLC now holds 8,591,401 shares worth roughly $72.51 million.
Then, Mattessich Antony C. sold 18,338 shares, generating $90,773 in total proceeds. Upon selling the shares at $4.95, the President and CEO now owns 427,943 shares.
Before that, Ozden Rabia Gurses sold 7,764 shares. Ocular Therapeutix Inc shares valued at $38,432 were divested by the Chief Medical Officer at a price of $4.95 per share. As a result of the transaction, Ozden Rabia Gurses now holds 92,767 shares, worth roughly $0.78 million.
BofA Securities initiated its Ocular Therapeutix Inc [OCUL] rating to a Buy in a research note published on February 09, 2024; the price target was $15. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. H.C. Wainwright revised its rating on August 10, 2021. It rated OCUL as “a Buy” which previously was an “a Neutral”.
Price Performance Review of OCUL
On Friday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock fall -0.35% to $8.44. Over the last five days, the stock has lost -7.25%. Ocular Therapeutix Inc shares have risen nearly 89.24% since the year began. Nevertheless, the stocks have risen 68.46% over the past one year. While a 52-week high of $11.31 was reached on 03/06/24, a 52-week low of $2.00 was recorded on 01/19/24. SMA at 50 days reached $8.12, while 200 days put it at $4.79. A total of 1.41 million shares were traded, compared to the trading of 0.81 million shares in the previous session.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 8.25, which if violated will result in even more drops to 8.07. On the upside, there is a resistance level at 8.68. A further resistance level may holdings at 8.93. The Relative Strength Index (RSI) on the 14-day chart is 41.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.71, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.40%. Stochastics %K at 7.28% indicates the stock is a buying.
How much short interest is there in Ocular Therapeutix Inc?
A steep rise in short interest was recorded in Ocular Therapeutix Inc stocks on Mar 15, 2024, growing by 5.19 million shares to a total of 9.16 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 3.97 million shares. There was a rise of 56.66%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.45% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.7.
